famotidine has been researched along with Barrett Esophagus in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Barrett Esophagus: A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine in high doses was well tolerated in this age group (mean 66." | 1.28 | High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study. ( Edge, DP, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Edge, DP | 1 |
1 other study available for famotidine and Barrett Esophagus
| Article | Year |
|---|---|
High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Drug Administration Schedule; Esophagitis, Peptic | 1990 |